AI tool to improve breast biopsy classification
Part of Cancer, Skin clinical trials.
This study tests an AI system that helps doctors classify breast biopsy results more accurately. It may lead to better treatment decisions for patients with breast abnormalities.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 89 years old.
- You have had an ultrasound-guided breast biopsy.
- If your biopsy was classified as B3, you have had a follow-up surgical sample or at least 12 months of clinical follow-up.
- For the prospective part, you must sign a consent form to participate.
- For the prospective part, you must be willing to have your data collected.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether an artificial intelligence (AI) system can better find the small markers placed during breast biopsies using ultrasound images. It may help improve how these markers are detected in the future.
This study tests whether an AI tool can predict how well breast cancer responds to chemotherapy given before surgery. Your tumor sample from a needle biopsy will be analyzed to see if the AI's prediction matches your actual treatment outcome.
This trial tests an artificial intelligence (AI) model that looks at pictures of breast tissue to find cancer. It may help improve early detection and reduce the need for invasive tests.
This study tests a new artificial intelligence software called Kenko Breast AI+ that analyzes breast MRI scans to help doctors better detect and monitor breast cancer. If you've had or are planning to have a breast MRI for cancer concerns, this trial might be right for you.
This study tests whether an artificial intelligence (AI) system can help a second reader interpret routine breast screening mammograms. It may improve how consistently images are assessed, especially when the first reader calls them normal or benign.
This study tests a new computer-based education module created by artificial intelligence to help breast cancer patients understand their diagnosis and treatment options. The goal is to see if this tool helps patients feel more informed and prepared for their care.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.